Bovine papillomavirus E2 repressor mutant displays a high-copy-number phenotype and enhanced transforming activity

D J Riese 2nd, J Settleman, K Neary, D DiMaio, D J Riese 2nd, J Settleman, K Neary, D DiMaio

Abstract

The methionine codon at bovine papillomavirus type 1 nucleotide 3091 was mutated to determine whether it may serve as an initiation codon for an E2 transcriptional repressor protein and to determine the role of the repressor in the biological activities of the virus. A series of transient expression experiments with CV1 cells documented that the mutation reduced expression of repressor activity from the viral genome and resulted in increased expression of the E5 transforming gene. Viral genomes containing the mutation displayed enhanced transforming activity in several assays in mouse C127 cells, including focus formation, colony formation in agarose, and tumorigenicity. In transformed cells, the mutant viral DNA was maintained as a plasmid with approximately 500 genomes per cell, whereas the wild-type copy number was approximately 75. These results indicate that the wild-type bovine papillomavirus type 1 genome encodes an E2 repressor protein that moderates the viral transforming activity and allows maintenance of the viral DNA at a relatively low copy number.

References

    1. J Virol. 1986 Nov;60(2):626-34
    1. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92
    1. Nature. 1987 Jan 1-7;325(6099):70-3
    1. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1215-8
    1. EMBO J. 1987 Jan;6(1):145-52
    1. J Virol. 1987 Jul;61(7):2128-37
    1. Cell. 1987 Jul 3;50(1):69-78
    1. J Virol. 1987 Sep;61(9):2924-8
    1. EMBO J. 1987 Jul;6(7):1945-50
    1. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7880-4
    1. Methods Enzymol. 1983;100:468-500
    1. J Virol. 1985 Mar;53(3):955-65
    1. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1030-4
    1. Cell. 1985 Aug;42(1):183-91
    1. J Virol. 1986 Jan;57(1):1-6
    1. J Virol. 1986 Feb;57(2):475-80
    1. Virology. 1986 Apr 15;150(1):221-30
    1. Cell. 1986 Aug 29;46(5):741-52
    1. Cell. 1986 Aug 29;46(5):753-62
    1. Nucleic Acids Res. 1987 Dec 23;15(24):10267-84
    1. EMBO J. 1988 Feb;7(2):525-31
    1. EMBO J. 1988 Feb;7(2):533-9
    1. Oncogene. 1988 May;2(5):453-9
    1. EMBO J. 1988 Apr;7(4):1197-204
    1. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5864-8
    1. J Virol. 1988 Oct;62(10):3608-13
    1. J Virol. 1989 Jan;63(1):259-66
    1. EMBO J. 1988 Dec 1;7(12):3807-16
    1. Proc Natl Acad Sci U S A. 1989 Jan;86(2):510-4
    1. J Virol. 1989 Apr;63(4):1743-55
    1. Genes Dev. 1989 Apr;3(4):510-26
    1. J Virol. 1989 Jul;63(7):3151-4
    1. J Gen Virol. 1989 Jun;70 ( Pt 6):1593-9
    1. Mol Cell Biol. 1989 Dec;9(12):5563-72
    1. J Virol. 1990 Feb;64(2):950-6
    1. J Mol Biol. 1975 Nov 5;98(3):503-17
    1. J Mol Biol. 1977 Jun 15;113(1):237-51
    1. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7147-51
    1. Mol Cell Biol. 1986 Mar;6(3):859-69

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe